What annoys me with CYC is they don't emphasis timing issues in the year that they occur, only when the comparatives don't stack up, they will add one offs (gain on insurance settlement, competitive settlement, large Chinese order) in the prior year comparatives to normalise.
Also, CYC seem to have delayed the launch of Ultralute even further.
The only way I see decent revenue growth in the medium term is reg approval in the USA.
Ann: Cyclopharm Limited 1H2017 Results Investor Presentation, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.04 |
Change
0.045(4.52%) |
Mkt cap ! $115.5M | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.06 | $1.00 | $35.35K | 34.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 658 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 2683 | 2 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| CYC (ASX) Chart |